Elanco Animal Health Incorporated — Cyborg Score 8/10
Strong
Animal health pharmaceuticals and biologics
Strategic Profile
Elanco is executing on a multi-wave blockbuster pipeline strategy with over 10 major innovation projects with blockbuster potential and 5-6 expected blockbuster approvals between 2026 and 2031. The company is raising its outlook for the innovation basket to $1.15 billion in 2026, while improving net leverage ratio faster than planned, targeting under 3x by 2027.
Cyborg Score Rationale
Elanco demonstrated 10% organic constant currency revenue growth in Q1 2026 with Zenrelia reaching trailing 4-quarter blockbuster status and Credelio Quattro achieving accelerating market share gains. Adjusted EBITDA increased 21% in Q1 2026 compared to Q1 2025, reflecting strong execution and margin expansion.
Top Insights
Zenrelia achieved blockbuster status in Q1 2026 with Credelio Quattro accelerating, while all major species categories grew driven by the innovation basket and base business
Growth in 2025 spanned all four business quadrants with contributions from price and volume, with nine of the company's top 10 largest countries growing
Elanco established Elanco Ventures in June 2026, a corporate venture capital platform backed by a $25 million multi-year commitment to support innovation in animal health
The company expects revenue growth of 5% to 7% excluding foreign exchange impacts and royalty sales, with accelerating price contribution versus 2025
Named Competitors
Apoquel/Cytopoint — Companion animal dermatology and parasiticide products
Animal Health Portfolio — Veterinary pharmaceuticals and vaccines
Animal Health Division — Veterinary pharmaceuticals and biologics
Credelio Quattro — Multi-parasitic companion animal treatment
Recent Developments
(June 2026) Launched Elanco Ventures, a $25 million corporate venture capital platform to invest in early-stage animal health startups
(May 2026) Reported Q1 2026 results with 10% organic constant currency revenue growth and 21% Adjusted EBITDA increase
(February 2026) Provided full year 2026 guidance with updated revenue of $5,010-$5,085 million and Adjusted EBITDA of $975-$1,005 million
(Q1 2026) USDA approved Befrena™, a new anti-IL31 monoclonal antibody for canine allergic and atopic dermatitis with improved dosing interval
Open the full interactive Elanco Animal Health Incorporated report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.